{"analyses":[{"ciLowerLimit":"0.801","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.149","estimateComment":"HR was based on a Cox regression model (with treatment as the only covariate) stratified by factors defined above, and was relative to placebo with \\< 1 favoring Enzalutamide.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.6534","pValueComment":"P-value was based on a stratified log-rank test by PSA doubling time (\\< 6 months, \\>= 6 months) and prior or concurrent use of a bone targeting agent (yes, no) as per IXRS.","paramType":"Hazard Ratio (HR)","paramValue":"0.959","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.0","upperLimit":"22.1","value":"18.5"},{"groupId":"OG001","lowerLimit":"14.8","upperLimit":"22.1","value":"18.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"933"},{"groupId":"OG001","value":"468"}],"units":"Participants"}],"description":"Pain was assessed using the score from the Brief Pain Inventory-Short Form (BPI-SF) question 3: \"Please rate your pain by marking the box beside the number that best describes your pain at its worst in the last 24 hours.\" Time to this event was defined as the time from randomization to onset of pain progression, where pain progression was defined as a 2-point or more increase from baseline in the question 3 score. Participants without observed pain progression at the time of analysis were right censored at the date of last pain assessment for the purposes of analysis. Analysis was based on Kaplan-Meier estimates.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 4 capsules of Enzalutamide 40 mg each (total dose 160 mg per day) orally, once daily in double-blind and open-label phase (up to a maximum of 68.8 months) until radiographic progression. Participants after last dose of study drug, were followed up for safety up to 30 days, and were long term followed up (for survival status and new prostate cancer therapies) from last dose to the death date or last known survival date.","id":"OG000","title":"Enzalutamide 160 mg"},{"description":"Participants received 4 capsules of placebo (matched to Enzalutamide) orally, once daily in double blind phase (up to a maximum of 51.3 months) until radiographic progression. Participants were given an opportunity to switch to open-label enzalutamide after completion of double blind phase. Participants after last dose of study drug, were followed up for safety up to 30 days and were long term followed up (for survival status and new prostate cancer therapies) to the death date or last known survival date.","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"The ITT population was defined as all participants randomly assigned to study treatment and was based on randomized treatment assignment regardless of whether or not treatment was administered.","reportingStatus":"POSTED","timeFrame":"From randomization until onset of pain progression (until the data cut-off date of 28 June 2017, maximum duration of treatment: 42.8 months)","title":"Time to Pain Progression","type":"SECONDARY","unitOfMeasure":"months"}